Mechanisms of type-I- and type-II-interferon-mediated signalling

Nature Reviews Immunology

Volumn 5, Issue 5, 2005, Pages 375-386

  Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN;

ANTIVIRAL ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; HUMANS; INTERFERON TYPE I; INTERFERON TYPE II; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 18844457095     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1604     Document Type: Review

References (138)

1. Pestka, S., Langer, J. A., Zoon, K. C. & Samuel, C. E. Interferons and their actions. Annu. Rev. Biochem. 56, 727-777 (1987).
2. Pestka, S., Krause, C. D. & Walter, M. R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (2004).
3. Pestka, S. The human interferon α species and hybrid proteins. Semin. Oncol. 24, S9-4-S9-17 (1997).
4. Chen, J., Baig, E. & Fish, E. N. Diversity and relatedness among the type I interferons. J. Interfon Cytokine Res. 24, 687-698 (2004).
5. Platanias, L. C. & Fish, E. N. Signaling pathways activated by interferons. Exp. Hematol. 27, 1583-1592 (1999).
6. Parmar, S. & Platanias, L. C. Interferons: mechanisms of action and clinical applications. Curr. Opin. Oncol. 15, 431-439 (2003).
7. Pestka, S. et al. The interferon γ (IFN-γ) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev. 8, 189-206 (1997).
8. Bach, E. A., Aguet, M. & Schreiber, R. D. The IFN γ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563-591 (1997).
9. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B 147, 258-267 (1957).
10. Kotenko, S. V. et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4, 69-77 (2003).
11. Darnell, J. E., Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular proteins. Science 264, 1415-1420 (1994). A comprehensive review of the IFN-activated JAK-STAT-signalling pathways.
12. Ihle, J. N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol. 6, 1-35 (1995).
13. Platanias, L. C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol. Ther. 98, 129-142 (2003).
14. Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623-15628 (1998).
15. Schindler, C., Shuai, K., Prezioso, V. R. & Darnell, J. E. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809-813 (1992).
16. Fu, X. Y., Schindler, C., Improta, T., Aebersold, R. & Darnell, J. E. The proteins of ISGF-3, the interferon α-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl Acad. Sci. USA 89, 7840-7843 (1992).
17. Shuai, K., Schindler, C., Prezioso, V. R. & Darnell, J. E. Activation of transcription by IFN-γ tyrosine phosphoryMon of a 91 -kD DNA binding protein. Science 258, 1808-1812 (1992).
18. Silvennoinen, O., Ihle, J. N., Schlessinger, J. & Levy, D. E. Interferon-induced nuclear signaling by Jak protein tyrosine kinases. Nature 366, 583-585 (1993).
19. Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
20. Darnell, J. E. Stats and gene regulation. Science 277, 1630-1635 (1997). An excellent review of the mechanisms of STAT activation and the regulatory effects of STATs on gene transcription.
21. Aaronson, D. S. & Horvath C. M. A road map for those who don't know JAK-STAT. Science 296, 1653-1655 (2002).
22. Meinke, A., Barahmand-Pour, F., Wohrl, S., Stoiber, D. & Decker, T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol. Cell. Biol. 16, 6937-6944 (1996).
23. Farrar, J. D., Smith, J. D., Murphy, T. L. & Murphy, K. M. Recruitment of Stat4 to the human interferon-α/β receptor requires activated Stat2. J. Biol. Chem. 275, 2693-2697 (2000).
24. Torpey, N., Maher, S. E., Bothwell, A. L. & Pober, J. S. Interferon α but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells. J. Biol. Chem. 279, 26789-26796 (2004).
25. Matikainen, S. et al. Interferon-α activates multiple STAT proteins and upregulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood 93, 1980-1991 (1999).
26. Fasler-Kan, E., Pansky, A., Wiederkehr, M., Battegay, M. & Heim, M. H. Interferon-α activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur. J. Biochem. 254, 514-519 (1998).
27. Nguyen, K. B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297, 2063-2066 (2002).
28. Boehm, U., Klamp, T., Groot, M. & Howard, J. C. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15, 749-795 (1997).
29. Wen, Z., Zhong, Z. & Darnell, J. E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241-250 (1995).
30. Wen, Z. & Darnell, J. E. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 25, 2062-2067 (1997).
31. Varinou, L. et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-γ-dependent innate immunity. Immunity 19, 793-802 (2003).
32. Uddin, S. et al. Protein kinase C-δ (PKC-δ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 277, 14408-14416 (2002). The first identification of PKC-δ as an IFN-activated kinase that regulates the phosphorylation of STAT1 on Ser727.
33. Deb, D. K. et al. Activation of protein kinase C δ by IFN-γ. J. Immunol. 171, 267-273 (2003).
34. Kristof, A. S., Marks-Konczalik, J., Billings, E. & Moss, J. Stimulation of signal transducer and activator of transcription-1 (STAT 1)-dependent gene transcription by lipopolysaccharide and interferon-γ is regulated by mammalian target of rapamycin. J. Biol. Chem. 278, 33637-33644 (2003).
35. Choudhury, G. G. A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C-ε, and MAPK in mesangial cells regulates interferon-γ-induced STAT1α transcriptional activation. J. Biol. Chem. 279, 27399-27409 (2004).
36. 2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-γ. Proc. Natl Acad. Sci. USA 99, 5971-5976 (2002).
37. Zhang, J. J. et al. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc. Natl Acad. Sci. USA 93, 15092-15096 (1996).
38. Bhattacharya, S. et al. Cooperation of Stat2 and p300/CBP in signaling induced by interferon-α. Nature 383, 344-347 (1996).
39. Zhang, J. J. et al. Ser727-dependent recruitment of MCM5 by Stat1α in IFN-γ-induced transcriptional activation. EMBO J. 17, 6963-6971 (1998).
40. DaFonseca, C. J., Shu, F. & Zhang, J. J. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-γ. Proc. Natl Acad. Sci. USA 98, 3034-3039 (2001).
41. Hebbes, T. R., Thorne, A. W. & Crane-Robinson, C. A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J. 7, 1395-1402 (1988).
42. Paulson, M., Press, C., Smith, E., Tanese, E. & Levy, D. E. IFN-stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nature Cell Biol. 4, 140-147 (2002).
43. Huang, M. et al. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-α-inducible genes. Nature Cell Biol. 4, 774-781 (2002).
44. Zhu, M., John, S., Berg, M. & Leonard, W. J. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling. Cell 96, 121-130 (1999).
45. Nusinzon, I. & Horvath, C. M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100, 14742-14747 (2003). The first evidence that histone-deacetylase activity is required for IFN-dependent transcription.
46. Chang, H. M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101, 9578-9583 (2004).
47. Sakamoto, S., Potla, R. & Larner, A. C. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J. Biol. Chem. 279, 40362-40367 (2004).
48. Mayer, B. J., Hamaguchi, M. & Hanafusa, H. A novel viral oncogene with structural homology to phospholipase C. Nature 332, 272-275 (1988).
49. Feller, S, M. Crk family adaptors - signaling complex formation and biological roles. Oncogene 20, 6348-6371 (2001).
50. Ahmad, S., Alsayed, Y., Druker, B. J. & Platanias, L. C. The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. J. Biol. Chem. 272, 29991-29994 (1997).
51. Alsayed, Y. et al. Interferon-γ activates the C3G/Rap1 signaling pathway. J. Immunol. 164, 1800-1806 (2000).
52. Stork, P. J. Does Rap1 deserve a bad Rap? Trends Biochem. Sci. 28, 267-275 (2003).
53. Bos, J. L., de Rooij, J. & Reedquist, K. A. Rap1 signaling: adhering to new models. Nature Rev. Mol. Cell Biol. 2, 369-377 (2001).
54. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. & Noda, M. A ras-related gene with transformation suppressor activity. Cell 56, 77-84 (1989).
55. Schmitt, J. M. & Stork, P. J. Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol. Cell. Biol. 21, 3671-3683 (2001).
56. Lahlou, H. et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J. Biol. Chem. 278, 39356-39371 (2003).
57. Hattori, M. & Minato, N. Rap1 GTPase: functions, regulation and malignancy. J. Biochem. 134, 479-484 (2003).
58. Lekmine, F. et al. The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1. Biochem. Biophys. Res. Commun. 291, 744-750 (2002).
59. Platanias, L. C. et al. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp. Hematol. 27, 1315-1321 (1999).
60. Huang, C. C., You, J. L., Wu, M. Y. & Hsu, K. S. Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI•Rab5 complex. Potential role in (S)-3,5-dthydroxyphenylglycene-induced long-term depression. J. Biol. Chem. 279, 12286-12292 (2004).
61. Katagiri, K. et al. Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking. Nature Immunol. 5, 1045-1051 (2004).
62. Fish, E. N. et al. Activation of a CrkL-Stat5 signaling complex by type I interferons. J. Biol. Chem. 274, 571-573 (1999). The first report that CRKL forms DNA-binding complexes with STAT5 and functions as a nuclear adaptor for STAT5 in type-I-IFN-mediated signalling.
63. Grumbach, I. M. et al. Engagement of the CrkL adapter in interferon α signaling in BCR-ABL expressing cells. Br. J. Haematol. 112, 327-336 (2001).
64. Takahashi, Y., Lallemand-Breitenbach, V., Zhu, J. & de The, H. PML nuclear bodies and apoptosis. Oncogene 23, 2819-2824 (2004).
65. Uddin, S. et al. Role of Stat5 in type I interferon-signaling and transcriptional regulation. Biochem. Biophys. Res. Commun. 308, 325-330 (2003).
66. Schaeffer, H. J. & Weber, M. J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19, 2435-2444 (1999).
67. Chang, L. & Karin, M. Mammalian MAP kinase signaling cascades. Nature 410, 37-40 (2001).
68. Dong, C., Davis, R. J. & Flavell, R. A. MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72 (2002).
69. Hazzalin, C. A. & Mahadevan, L. C. MAPK-regulated transcription: a continuously variable gene switch? Nature Rev. Mol. Cell Biol. 3, 30-40 (2002).
70. Platanias, L. C. Map kinase signaling pathways and hematologic malignancies. Blood 101, 4667-4679 (2003).
71. Uddin, S. et al. Activation of the p38 Map kinase by type I interferons. J. Biol. Chem. 274, 30127-30131 (1999).
72. Goh, K. C., Haque, S. J. & Williams, B. R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18, 5601-5608 (1999).
73. Uddin, S. et al. The Rac1/p38 Map kinase pathway is required for IFNα-dependent transcriptional activation but not serine phosphorylation of Stat-proteins. J. Biol. Chem. 275, 27634-27640 (2000).
74. Kovarik, P. et al. Stress-induced phosphorylation of Stat1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different pathway. Proc. Natl Acad. Sci. USA 96, 13956-13961 (1999).
75. Li, Y. et al. Role of p38α Map kinase in type I interferon signaling. J. Biol. Chem. 279, 970-979 (2004). Definitive evidence that the type-I-IFN-activated p38-signalling pathway is required for transcriptional regulation.
76. Ramsauer, K. et al. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc. Natl Acad. Sci. USA 99, 12859-12864 (2002).
77. Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S. & Bustelo, X. R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385, 169-172 (1997).
78. Bustelo, X. R. Regulatory and signaling properties of the Vav family. Mol. Cell. Biol. 20, 1461-1477 (2000).
79. Platanias, L. C. & Sweet, M. E. Interferon α induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells. J. Biol. Chem. 269, 3143-3146 (1994).
80. Vav is associated to the IFNα/β receptor and contributes to the antiproliferative effect of IFNα in megacaryccytic cell lines. Oncogene 19, 387-394 (2000).
81. Uddin, S., Sweet, M. E., Colamonici, O. R., Krolewski, J. J. & Platanias, L. C. The vav proto-oncogene product interacts with the Tyk-2 tyrosine kinase. FEBS Lett. 403, 31-34 (1997).
82. Li, Y. et al. Activation of Mkk3 and Mkk6 by type I interferons. J. Biol. Chem. 280, 10001-10010 (2005).
83. Kotlyarov, A. & Gaestel, M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression? Biochem. Soc. Trans. 30, 959-963 (2002).
84. Deak, M., Clifton A. D., Lucocq, L. M. & Alessi, D. R. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MARK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 17, 4426-4441 (1998).
85. Soloaga, A. et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 22, 2788-2797 (2003).
86. Clayton, A. L. & Mahadevan, L. C. MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett. 546, 51-58 (2003).
87. Waskiewicz, A. J., Flynn, A., Proud, C. G. & Cooper, J. A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16, 1909-1920 (1997).
88. Knauf, U., Tschopp, C. & Gram, H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell. Biol. 21, 5500-5511 (2001).
89. Mayer, I. A. et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells. J. Biol. Chem. 276, 28570-28577 (2001).
90. Verma, A. et al. Activation of the p38 Map kinase pathway mediates the suppressive effects of type I interferons and transforming growth factor β on normal hematopoiesis. J. Biol. Chem. 277, 7726-7735 (2002).
91. Ishida, H. et al. Involvement of p38 signaling pathway in interferon-α-mediated antiviral activity towards hepatitis C virus. Biochem. Blophys. Res. Commun. 321, 722-727 (2004).
92. Katze, M. G., He, Y. & Gale, M. Viruses and interferon: a fight for supremacy. Nature Rev. Immunol. 2, 675-687 (2002). An excellent review of the mechanisms by which IFNs mediate antiviral effects.
93. David, M. et al. Requirement for MAP kinase (ERK2) activity in interferon α- and interferon β-stimulated gene expression through STAT proteins. Science 269, 1721-1723 (1995).
94. Hu, J. et al. ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-β-dependent gene transcription in response to interferon-γ. J. Biol. Chem. 276, 287-297 (2001).
95. Wang, F. et al, Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nature Immunol. 5, 1266-1274 (2004).
96. Roy, S. K. et al. MEKK1 plays a critical role in activating the transcription factor C/EBP-β-dependent gene expression in response to IFN-γ. Proc. Natl Acad. Sci. USA 99, 7945-7950 (2002).
97. Roy, S. K., Wachira, S. J., Weihua, X., Hu, J. & Kalvakolanu, D. V. CCAAT/enhancer-binding protein-β regulates interferon-induced transcription through a novel element. J. Biol. Chem. 275, 12626-12632 (2000).
98. Floyd, Z. E. & Stephens, J. M. Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes. J. Biol. Chem. 277, 4062-4068 (2002).
99. Li, C. et al. IFNα induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 23, 1608-1617 (2004).
100. Li, G., Xiang, Y., Sabapathy, K. & Silverman, R. H. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J. Biol. Chem. 279, 1123-1131 (2004).
101. Uddin, S. et al. Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J. Biol. Chem. 270, 15938-159341 (1995).
102. White, M. F. Insulin signaling in health and disease. Science 302, 1710-1711 (2003).
103. Platanias, L. C. et al. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J. Biol. Chem. 271, 278-282 (1996).
104. Burfoot, M. S. et al. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. J. Biol. Chem. 272, 24183-24190 (1997).
105. Uddin, S. et al. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-α receptors. Blood 90, 2574-2582 (1997).
106. Uddin, S. et al. Interferon-dependent activation of the serine kinase PI 3′-kinase requires engagement of the IRS pathway but not the Stat pathway. Biochem. Biophys. Res. Commun. 270, 158-162 (2000).
107. Uddin, S. et al. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-α. J. Immunol. 158, 2390-2397 (1997).
108. Cengel, K. A. & Freund, G. G. JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation. J. Biol. Chem. 274, 27969-27974 (1999).
109. Nguyen, H., Ramana, C. V., Bayes, J. & Stark, G. R. Roles of phosphatidylinositol 3-kinase in interferon-γ-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J. Biol. Chem. 276, 33361-33368 (2001).
110. DeVries, T. A., Rachelle, L., Kalkofen, A., Matassa, A. & Reyland, M. E. Protein kinase Cδ regulates apoptosis via activation of STAT1. J. Biol. Chem. 279, 45603-45612 (2004).
111. Lu, Z. et al. Tumor promotion by depleting cells of protein kinase C-δ. Mol. Cell. Biol. 17, 3418-3428 (1997).
112. Redding, P. J. et al. Transgenic mice overexpressing protein kinase C δ in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 59, 5710-5718 (1999).
113. Srivastava, K. K. et al. Engagement of protein kinase C-θ in interferon signaling in T-cells. J. Biol. Chem. 279, 29911-29920 (2004).
114. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-501 (2002).
115. Barca, O. et al. Interferon β promotes survival in primary astrocytes through phosphatidylinositol 3-kinase. J. Neuroimmmunol. 139, 155-159 (2003).
116. Ruuth, K., Carlsson, L., Hallberg, B. & Lundgren, E. Interferon-α promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase. Biochem. Biophys. Res. Commun. 284, 583-586 (2001).
117. Wang, K. et al. Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-δ, and NF-κB signaling pathways. J. Immunol. 171, 1035-1041 (2003).
118. Yang, C. H. et al. Interferon α/β promotes cell survival by activating nuclear factor κB through phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 276, 13756-13761 (2001).
119. Thyrell, L. et al. Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/ mammalian target of rapamycin signaling pathway. J. Biol. Chem. 279, 24152-24162 (2004).
120. Hwang, S. Y. et al. LY294002 inhibits interferon-γ-stimulated inducible nitric oxide synthase expression in BV2 microglial cells. Biochem. Biophys. Res. Commun. 318, 691-697 (2004).
121. Navarro, A., Anand-Apte, B., Tanabe, Y., Feldman, G. & Larner, A. C. A PI-3 kinase-dependent, Stat1-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J. Leukoc. Biol. 73, 540-545 (2003).
122. Rani, M. R., Hibbert, L., Sizemore, N., Stark, G. R. & Ransohoff, R. M. Requirement of phosphoinositide 3-kinase and Akt for interferon-β- mediated induction of the β-R1 (SCYB11) gene. J. Biol. Chem. 277, 38456-38461 (2002).
123. Marcus, P. I. & Sab, J. M. Molecular basis of interferon action: inhibition of viral RNA translation. Virology 30, 502-516 (1966).
124. Doualla-Bell, F. & Koromilas, A. E. Induction of PG G/H synthase-2 in bovine myometrial cells by interferon-τ requires the activation of the p38 MARK pathway. Endocrinology 142, 5107-5115 (2001).
125. Lekmine, F. et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 278, 27772-27780 (2003). The first report that type IIFNs activate pathways for the initiation of mRNA translation that are downstream of MTOR.
126. Lekmine, F. et al. Interferon-γ engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp. Cell Res. 295, 173-182 (2004).
127. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 (2004). A comprehensive review of MTOR and the regulation of signals for mRNA translation.
128. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nature Rev. Cancer 4, 335-348 (2004).
129. Gingras, A. C. et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864 (2001).
130. Lal, L. et al. Activation of the p70 S6 kinase by all-transretinoic acid in acute promyelocytic leukemia cells. Blood 105, 1669-1677 (2005).
131. Garber, K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J. Natl Cancer Inst. 93, 1517-1519 (2001).
132. Ramana, C. V., Gil, P. M., Schreiber, R. D. & Stark, G. R. Stat1-dependent and -independent pathways in IFN-γ-dependent signaling. Trends Immunol. 23, 96-101 (2002).
133. Sizemore, N. et al. Inhibitor of κB kinase is required to activate a subset of interferon γ-stimulated genes. Proc. Natl Acad. Sci. USA 101, 7994-7998 (2004).
134. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
135. Deane, J. A. & Fruman, D. A. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22, 563-598 (2004).
136. Malik, A. H. & Lee, W. M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. 132, 723-731 (2000).
137. Liang, T. J., Rehermann, B., Seeff, L. B. & Hoofnagle, J. H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305 (2000).
138. Loutfy, M. R. et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290, 3222-3228 (2003).